1 December 2025 - The December 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes has a few new/revised listings of note:

• Apomorphine hydrochloride hemihydrate (Movapo POD) - new formulation
• Bimekizumab (Bimzelx) - new indication
• Cabozantinib mesylate (Cabometyx) - new indication
• Cannabidiol (Epidyolex) - restriction change
• Ocrelizumab with hyaluronidase (human, recombinant) (Ocrevus) - new formulation
• Pegcetacoplan (Empaveli) - new indication
• Toripalimab (Zytorvi) - new medicine

Read summary of PBS changes